Abstract:Background The canonical Wnt signaling is concurrently important for osteoblast differentiation and myeloma cell proliferation. Its activation in myeloma cells and its inhibition in osteoblasts and their progenitors have been identified in the previous studies. Osteoblast progenitors and myeloma cells from a myeloma patient share the same bone marrow (BM) microenvironment, but respond differently to DKK-1 secreted by myeloma cells. The mechanisms remain unclear. Methods Primary multiple myeloma (MM) cells were isolated from BM mononuclear cells of 12 MM patients. Human bone marrow stromal cells (SCs) were obtained from BM adherent cells of these MM patients and 10 healthy donors. The mRNA expression levels of DKK-1 binding receptor LRP5/6 and Kremen1/2 (Krm1/2) were analyzed by Real-time PCR in human myeloma cell line (HMCL) RPMI-8226, NCI-H929, U266, LP-1, CZ-1, KM-3, Sko-007, primary myeloma cells and SCs from 12 MM patients and SCs from 10 healthy donors. The binding capability of DKK-1 binding receptors to DKK-1 on primary myeloma cells and SCs was detected by flow cytometry assay. Results The mRNA expression levels of DKK-1 binding receptor LRP5/6 and Krm1/2 in SCs from patients with MM were significantly higher than those in myeloma cells and in SCs from healthy donors. The binding capability to DKK-1of DKK-1 binding receptors on SCs from MM patients was obviously higher than those on myeloma cells and SCs from healthy donors by flow cytometry assay. Similar to the effects of coculture with rhDKK1, coculture of SCs from healthy donors with myeloma cells in the presence or absence of a Transwell insert did up-regulate SCs' mRNA levels of LRP5/6 and Krm1/2, and down-regulate their mRNA levels of β-catenin. Conclusion Compared with myeloma cells, the SCs from MM patients overexpress DKK-1 binding receptors LRP5/6 and Krm1/2 in response to DKK-1 secreted by myeloma cells, which results in intracellular Wnt signaling inhibition. Our study provides a novel insight into mechanisms of myeloma associated osteolytic lesions.

COX2 confers bone marrow stromal cells to promoting TNFα/TNFR1β-mediated myeloma cell growth and adhesion

CXCL10 recruitment of γδ T cells into the hypoxic bone marrow environment leads to IL-17 expression and multiple myeloma progression

Interleukin-32 Alpha Promotes The Proliferation Of Multiple Myeloma Cells By Inducing Production Of Il-6 In Bone Marrow Stromal Cells

Bone Marrow Stromal Cells Protect Myeloma Cells from Ferroptosis through GPX4 deSUMOylation

Interleukin-32 Induce Production of Il-6 in Multiple Myeloma Bone Marrow Stromal Cells

Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Cox-2 Promotes Metastasis In Nasopharyngeal Carcinoma By Mediating Interactions Between Cancer Cells And Myeloid-Derived Suppressor Cells

Bone Marrow Stromal Cells Induced Activation of Nuclear Factor Κb Signaling Protects Non-Hodgkin’s B Lymphoma Cells from Apoptosis

TNF-α-induced alterations in stromal progenitors enhance leukemic stem cell growth via CXCR2 signaling

Overexpression of cyclooxygenase-2 in multiple myeloma: association with reduced survival

In vitro models of the crosstalk between multiple myeloma and stromal cells recapitulate the mild NF-κB activation observed in vivo

Characterization of the biological and transcriptomic landscapes of bone marrow-derived mesenchymal stem cells in patients with multiple myeloma

Bone marrow-derived mesenchymal stem cells promote cell proliferation of multiple myeloma through inhibiting T cell immune responses via PD-1/PD-L1 pathway

Differential expression of DKK-1 binding receptors on stromal cells and myeloma cells results in their distinct response to secreted DKK-1 in myeloma

Lymphotoxin - β promotes breast cancer bone metastasis colonization and osteolytic outgrowth

CCR2-dependent recruitment of macrophages by tumor-educated mesenchymal stromal cells promotes tumor development and is mimicked by TNFα.

Crosstalk Between Bone Marrow-Derived Myofibroblasts and Gastric Cancer Cells Regulates Cancer Stemness and Promotes Tumorigenesis

Dual therapeutic targeting of MYC and JUNB transcriptional programs for enhanced anti-myeloma activity

Cross-Talking Between Bone Marrow-Derived Cells and Lung Cancer Cells

Expressions of IL-1β,IL-6,SCF,TPO on Bone Marrow Stromal Cells in Patients with Multiple Myelo-Ma

CXCL8/CXCR2 Signaling Mediates Bone Marrow Fibrosis and Represents a Therapeutic Target in Myelofibrosis